Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Non-Small-Cell Lung | 27 | 2021 | 5379 | 0.860 |
Why?
|
Lung Neoplasms | 42 | 2021 | 13446 | 0.760 |
Why?
|
Quinazolines | 11 | 2016 | 1366 | 0.620 |
Why?
|
Receptor Protein-Tyrosine Kinases | 9 | 2017 | 1621 | 0.440 |
Why?
|
Adenocarcinoma | 21 | 2017 | 6360 | 0.420 |
Why?
|
Antineoplastic Agents | 22 | 2021 | 13631 | 0.380 |
Why?
|
Carboplatin | 4 | 2015 | 787 | 0.310 |
Why?
|
Paclitaxel | 3 | 2009 | 1726 | 0.280 |
Why?
|
Protein Kinase Inhibitors | 14 | 2018 | 5691 | 0.280 |
Why?
|
Mutation | 17 | 2021 | 30192 | 0.270 |
Why?
|
Antimetabolites, Antineoplastic | 4 | 2006 | 645 | 0.250 |
Why?
|
Genes, erbB-1 | 2 | 2017 | 161 | 0.230 |
Why?
|
Exons | 5 | 2018 | 2393 | 0.230 |
Why?
|
Proto-Oncogene Proteins c-met | 3 | 2016 | 561 | 0.210 |
Why?
|
Pyrazoles | 4 | 2017 | 2031 | 0.200 |
Why?
|
Pyridines | 4 | 2017 | 2885 | 0.180 |
Why?
|
Mutagenesis, Insertional | 4 | 2018 | 662 | 0.180 |
Why?
|
Proto-Oncogene Proteins | 6 | 2017 | 4520 | 0.170 |
Why?
|
Postoperative Care | 1 | 2006 | 1475 | 0.170 |
Why?
|
Deoxycytidine | 3 | 2008 | 886 | 0.150 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 10 | 2018 | 11858 | 0.150 |
Why?
|
HSP90 Heat-Shock Proteins | 2 | 2018 | 422 | 0.150 |
Why?
|
Neoplasm Staging | 12 | 2021 | 11196 | 0.130 |
Why?
|
Gene Rearrangement | 3 | 2017 | 1143 | 0.130 |
Why?
|
Salvage Therapy | 2 | 2010 | 1272 | 0.130 |
Why?
|
Drug Resistance, Neoplasm | 6 | 2017 | 5333 | 0.130 |
Why?
|
Interferon Type I | 3 | 1996 | 567 | 0.130 |
Why?
|
Radiation Injuries | 2 | 2017 | 1181 | 0.130 |
Why?
|
Carcinoma, Small Cell | 5 | 2005 | 420 | 0.120 |
Why?
|
Cisplatin | 4 | 1995 | 1654 | 0.120 |
Why?
|
Fluorouracil | 5 | 1998 | 1648 | 0.120 |
Why?
|
Survival Rate | 12 | 2020 | 12822 | 0.110 |
Why?
|
Protein Interaction Domains and Motifs | 1 | 2016 | 446 | 0.110 |
Why?
|
Aged | 49 | 2021 | 171163 | 0.100 |
Why?
|
Protein-Tyrosine Kinases | 3 | 2017 | 2423 | 0.100 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2017 | 904 | 0.100 |
Why?
|
Carcinoma | 3 | 2008 | 2311 | 0.100 |
Why?
|
Lung Diseases, Interstitial | 1 | 2000 | 940 | 0.090 |
Why?
|
ras Proteins | 2 | 2013 | 1054 | 0.090 |
Why?
|
PTEN Phosphohydrolase | 1 | 2017 | 1117 | 0.090 |
Why?
|
Gene Amplification | 1 | 2015 | 1088 | 0.090 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2015 | 340 | 0.090 |
Why?
|
HIV | 1 | 2018 | 1587 | 0.090 |
Why?
|
Deglutition Disorders | 1 | 2017 | 640 | 0.090 |
Why?
|
Radiotherapy | 2 | 2017 | 1491 | 0.090 |
Why?
|
Alternative Splicing | 1 | 2015 | 1103 | 0.090 |
Why?
|
Liver Neoplasms | 4 | 1997 | 4349 | 0.090 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2015 | 452 | 0.080 |
Why?
|
Bronchi | 1 | 2013 | 843 | 0.080 |
Why?
|
Middle Aged | 46 | 2021 | 223016 | 0.080 |
Why?
|
Peripheral Nervous System Diseases | 1 | 1995 | 710 | 0.080 |
Why?
|
Endosonography | 1 | 2013 | 626 | 0.080 |
Why?
|
Drug Administration Schedule | 6 | 2020 | 4851 | 0.080 |
Why?
|
Female | 54 | 2021 | 396141 | 0.080 |
Why?
|
Aged, 80 and over | 18 | 2021 | 59496 | 0.070 |
Why?
|
Interferon-alpha | 2 | 1991 | 909 | 0.070 |
Why?
|
Humans | 71 | 2021 | 765926 | 0.070 |
Why?
|
Triazoles | 1 | 2013 | 898 | 0.070 |
Why?
|
Male | 48 | 2021 | 363815 | 0.070 |
Why?
|
Glutathione | 1 | 2009 | 588 | 0.070 |
Why?
|
Disease-Free Survival | 3 | 2017 | 6838 | 0.070 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2021 | 3542 | 0.070 |
Why?
|
Follow-Up Studies | 10 | 2018 | 39228 | 0.070 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2017 | 2945 | 0.070 |
Why?
|
Nasopharyngeal Neoplasms | 1 | 2008 | 287 | 0.060 |
Why?
|
Glyburide | 1 | 2006 | 117 | 0.060 |
Why?
|
Interleukin-2 | 2 | 1991 | 1894 | 0.060 |
Why?
|
Etoposide | 4 | 2015 | 636 | 0.060 |
Why?
|
ACTH Syndrome, Ectopic | 1 | 2005 | 30 | 0.060 |
Why?
|
Receptor, erbB-2 | 1 | 2016 | 2592 | 0.060 |
Why?
|
Pancreatic Neoplasms | 3 | 2006 | 5450 | 0.060 |
Why?
|
Inappropriate ADH Syndrome | 1 | 2005 | 59 | 0.060 |
Why?
|
Adult | 36 | 2020 | 223088 | 0.060 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2007 | 637 | 0.060 |
Why?
|
Thoracotomy | 1 | 2006 | 374 | 0.060 |
Why?
|
Carcinoembryonic Antigen | 1 | 1986 | 336 | 0.060 |
Why?
|
Antibodies, Neoplasm | 1 | 1986 | 282 | 0.060 |
Why?
|
Retrospective Studies | 14 | 2020 | 81537 | 0.060 |
Why?
|
Necrosis | 1 | 2008 | 1611 | 0.060 |
Why?
|
Antibodies, Monoclonal | 3 | 2010 | 9239 | 0.060 |
Why?
|
Genotype | 6 | 2015 | 13026 | 0.060 |
Why?
|
Carcinoma, Hepatocellular | 1 | 1996 | 2325 | 0.050 |
Why?
|
Thiazolidinediones | 1 | 2006 | 459 | 0.050 |
Why?
|
Remission Induction | 3 | 2010 | 2413 | 0.050 |
Why?
|
Treatment Outcome | 13 | 2020 | 65194 | 0.050 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2007 | 1150 | 0.050 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2006 | 12235 | 0.050 |
Why?
|
Lymphoma | 4 | 2017 | 1896 | 0.050 |
Why?
|
Lymph Nodes | 1 | 2013 | 3447 | 0.050 |
Why?
|
Lung | 1 | 2000 | 10046 | 0.050 |
Why?
|
Combined Modality Therapy | 5 | 2006 | 8522 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 2 | 2015 | 6503 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2018 | 10727 | 0.050 |
Why?
|
Cell Line, Tumor | 5 | 2018 | 17060 | 0.050 |
Why?
|
Molecular Targeted Therapy | 3 | 2018 | 2823 | 0.050 |
Why?
|
Infusions, Intravenous | 2 | 1996 | 2227 | 0.040 |
Why?
|
Smoking | 2 | 2017 | 9082 | 0.040 |
Why?
|
Monoamine Oxidase Inhibitors | 1 | 2000 | 152 | 0.040 |
Why?
|
Drug Evaluation | 4 | 1991 | 642 | 0.040 |
Why?
|
Monoamine Oxidase | 1 | 2000 | 179 | 0.040 |
Why?
|
Indans | 1 | 2000 | 92 | 0.040 |
Why?
|
Serial Learning | 1 | 2000 | 41 | 0.040 |
Why?
|
Carcinoma, Bronchogenic | 1 | 1980 | 86 | 0.040 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2013 | 4044 | 0.040 |
Why?
|
Levodopa | 1 | 2000 | 221 | 0.040 |
Why?
|
Prognosis | 7 | 2018 | 29890 | 0.040 |
Why?
|
Antiparkinson Agents | 1 | 2000 | 184 | 0.040 |
Why?
|
Uranium | 1 | 1999 | 24 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 2 | 2015 | 20690 | 0.040 |
Why?
|
Basal Ganglia Diseases | 1 | 2000 | 145 | 0.040 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2017 | 2510 | 0.040 |
Why?
|
Mining | 1 | 1999 | 93 | 0.040 |
Why?
|
Angiogenesis Inhibitors | 1 | 2008 | 2046 | 0.040 |
Why?
|
Rectal Neoplasms | 3 | 1997 | 1183 | 0.040 |
Why?
|
DNA Mutational Analysis | 3 | 2013 | 4111 | 0.040 |
Why?
|
Recombinant Proteins | 5 | 1996 | 6491 | 0.040 |
Why?
|
Herpes Zoster | 1 | 1980 | 252 | 0.040 |
Why?
|
Brain Injuries | 1 | 2008 | 2061 | 0.030 |
Why?
|
Heartburn | 1 | 2017 | 71 | 0.030 |
Why?
|
Motor Skills | 1 | 2000 | 517 | 0.030 |
Why?
|
Chemoembolization, Therapeutic | 1 | 1997 | 128 | 0.030 |
Why?
|
Colorectal Neoplasms | 2 | 1995 | 6958 | 0.030 |
Why?
|
Colonic Neoplasms | 3 | 1997 | 2530 | 0.030 |
Why?
|
Prednisone | 1 | 2000 | 1566 | 0.030 |
Why?
|
Tumor Cells, Cultured | 2 | 2016 | 6101 | 0.030 |
Why?
|
Brain Neoplasms | 2 | 2015 | 9065 | 0.030 |
Why?
|
Sequence Deletion | 2 | 2013 | 1494 | 0.030 |
Why?
|
Mediastinum | 1 | 2017 | 271 | 0.030 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2017 | 238 | 0.030 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 2 | 2013 | 1763 | 0.030 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 1999 | 540 | 0.030 |
Why?
|
DNA, Neoplasm | 2 | 2013 | 1739 | 0.030 |
Why?
|
Biopsy, Needle | 1 | 1980 | 1613 | 0.030 |
Why?
|
Time Factors | 4 | 2021 | 40097 | 0.030 |
Why?
|
Injections, Subcutaneous | 1 | 1996 | 682 | 0.030 |
Why?
|
Survival Analysis | 4 | 2004 | 10086 | 0.030 |
Why?
|
Leukemia | 2 | 1996 | 1522 | 0.030 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2010 | 9373 | 0.030 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2016 | 347 | 0.030 |
Why?
|
Structural Homology, Protein | 1 | 2013 | 86 | 0.030 |
Why?
|
Drug Therapy, Combination | 4 | 2009 | 6306 | 0.030 |
Why?
|
Ataxia | 1 | 1996 | 307 | 0.030 |
Why?
|
Immunohistochemistry | 2 | 2018 | 11030 | 0.030 |
Why?
|
Reaction Time | 1 | 2000 | 2085 | 0.030 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2018 | 1331 | 0.030 |
Why?
|
Camptothecin | 1 | 1996 | 598 | 0.030 |
Why?
|
Administration, Oral | 2 | 2004 | 4016 | 0.030 |
Why?
|
Mucous Membrane | 1 | 1996 | 658 | 0.030 |
Why?
|
Cholangiocarcinoma | 1 | 1998 | 577 | 0.030 |
Why?
|
Bile Duct Neoplasms | 1 | 1998 | 624 | 0.030 |
Why?
|
Base Sequence | 2 | 2013 | 12405 | 0.020 |
Why?
|
Prospective Studies | 5 | 2021 | 54807 | 0.020 |
Why?
|
Disease Progression | 3 | 2015 | 13614 | 0.020 |
Why?
|
Proton Pump Inhibitors | 1 | 2017 | 551 | 0.020 |
Why?
|
Apoptosis | 1 | 2007 | 9505 | 0.020 |
Why?
|
HIV Infections | 1 | 2018 | 17531 | 0.020 |
Why?
|
Hospitals, University | 1 | 2013 | 573 | 0.020 |
Why?
|
Genomic Instability | 1 | 2015 | 716 | 0.020 |
Why?
|
Prostatic Neoplasms | 3 | 2005 | 11090 | 0.020 |
Why?
|
Occupational Diseases | 1 | 1999 | 1456 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2000 | 2155 | 0.020 |
Why?
|
Neoplastic Cells, Circulating | 2 | 1993 | 949 | 0.020 |
Why?
|
Anti-Inflammatory Agents | 1 | 2000 | 1802 | 0.020 |
Why?
|
Neutropenia | 1 | 1996 | 894 | 0.020 |
Why?
|
Membrane Proteins | 1 | 2007 | 7847 | 0.020 |
Why?
|
Genomics | 2 | 2018 | 5925 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2015 | 1835 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2018 | 3604 | 0.020 |
Why?
|
Leukocyte Count | 2 | 1991 | 1605 | 0.020 |
Why?
|
Vena Cava, Inferior | 1 | 1993 | 463 | 0.020 |
Why?
|
Hepatic Artery | 2 | 1997 | 233 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2015 | 2844 | 0.020 |
Why?
|
Neoplasms | 3 | 1996 | 22340 | 0.020 |
Why?
|
Crystallography, X-Ray | 1 | 2013 | 1944 | 0.020 |
Why?
|
Cytotoxins | 1 | 2009 | 154 | 0.020 |
Why?
|
Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2008 | 83 | 0.020 |
Why?
|
Anal Canal | 1 | 1991 | 376 | 0.020 |
Why?
|
Biopsy, Fine-Needle | 1 | 2013 | 1130 | 0.020 |
Why?
|
Laparoscopy | 1 | 1980 | 2037 | 0.020 |
Why?
|
Carcinoma, Large Cell | 1 | 2008 | 114 | 0.020 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2016 | 1609 | 0.020 |
Why?
|
Headache | 1 | 1996 | 1261 | 0.020 |
Why?
|
Oncogenes | 1 | 2013 | 1232 | 0.020 |
Why?
|
Radiography | 3 | 2015 | 6941 | 0.020 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2017 | 2877 | 0.020 |
Why?
|
Injections, Intravenous | 1 | 2009 | 1376 | 0.020 |
Why?
|
Organoplatinum Compounds | 1 | 2008 | 405 | 0.020 |
Why?
|
Breast Neoplasms | 4 | 2017 | 21069 | 0.020 |
Why?
|
Eosinophils | 1 | 1991 | 946 | 0.020 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2002 | 1777 | 0.020 |
Why?
|
Parkinson Disease | 1 | 2000 | 2885 | 0.020 |
Why?
|
Gene Frequency | 1 | 2013 | 3623 | 0.020 |
Why?
|
Lymphoma, B-Cell | 1 | 1993 | 943 | 0.020 |
Why?
|
Protein Conformation | 1 | 2013 | 3945 | 0.020 |
Why?
|
Maximum Tolerated Dose | 1 | 2008 | 895 | 0.020 |
Why?
|
T-Lymphocytes | 2 | 1980 | 10256 | 0.020 |
Why?
|
Cell Survival | 1 | 2015 | 5745 | 0.020 |
Why?
|
Liver Cirrhosis | 1 | 1996 | 1961 | 0.020 |
Why?
|
Lymphatic Metastasis | 2 | 1991 | 2885 | 0.020 |
Why?
|
Skin Neoplasms | 3 | 1990 | 5836 | 0.020 |
Why?
|
Catheterization, Central Venous | 1 | 1990 | 538 | 0.010 |
Why?
|
Retroviridae Infections | 1 | 1985 | 148 | 0.010 |
Why?
|
Phosphorylation | 1 | 2015 | 8279 | 0.010 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 1986 | 340 | 0.010 |
Why?
|
Vinblastine | 1 | 1986 | 483 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2013 | 6058 | 0.010 |
Why?
|
Papio | 1 | 1986 | 671 | 0.010 |
Why?
|
Floxuridine | 1 | 1983 | 44 | 0.010 |
Why?
|
Models, Molecular | 1 | 2013 | 5377 | 0.010 |
Why?
|
Ovarian Neoplasms | 1 | 2000 | 4904 | 0.010 |
Why?
|
Lymphocytes | 1 | 1991 | 2601 | 0.010 |
Why?
|
Infusions, Intra-Arterial | 1 | 1983 | 219 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2009 | 3430 | 0.010 |
Why?
|
Sezary Syndrome | 2 | 1980 | 70 | 0.010 |
Why?
|
Area Under Curve | 1 | 2006 | 1637 | 0.010 |
Why?
|
Stomach Neoplasms | 1 | 1993 | 1469 | 0.010 |
Why?
|
Cardiomyopathy, Dilated | 1 | 1988 | 844 | 0.010 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2008 | 781 | 0.010 |
Why?
|
Random Allocation | 2 | 1985 | 2394 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2013 | 13398 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2018 | 6542 | 0.010 |
Why?
|
Biopsy | 1 | 2014 | 6766 | 0.010 |
Why?
|
Mycosis Fungoides | 2 | 1980 | 154 | 0.010 |
Why?
|
Self Report | 1 | 2013 | 3768 | 0.010 |
Why?
|
Brain | 1 | 2008 | 27179 | 0.010 |
Why?
|
Warfarin | 1 | 1990 | 1494 | 0.010 |
Why?
|
Hearing Loss | 1 | 2008 | 785 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2013 | 17596 | 0.010 |
Why?
|
Point Mutation | 1 | 2006 | 1590 | 0.010 |
Why?
|
Acquired Immunodeficiency Syndrome | 2 | 1990 | 2204 | 0.010 |
Why?
|
Tamoxifen | 1 | 1985 | 964 | 0.010 |
Why?
|
Cohort Studies | 2 | 2020 | 41680 | 0.010 |
Why?
|
Basal Ganglia Hemorrhage | 1 | 2000 | 8 | 0.010 |
Why?
|
Paired-Associate Learning | 1 | 2000 | 54 | 0.010 |
Why?
|
Prevalence | 1 | 2017 | 15828 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2016 | 15401 | 0.010 |
Why?
|
Exanthema | 1 | 2004 | 503 | 0.010 |
Why?
|
Health Physics | 1 | 1999 | 35 | 0.010 |
Why?
|
Colorado | 1 | 1999 | 167 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2018 | 18292 | 0.010 |
Why?
|
Herpesvirus 3, Human | 1 | 1980 | 157 | 0.010 |
Why?
|
Kidney Neoplasms | 2 | 1993 | 4278 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2014 | 14643 | 0.010 |
Why?
|
Dominance, Cerebral | 1 | 2000 | 616 | 0.010 |
Why?
|
Estrogens | 1 | 1985 | 1528 | 0.010 |
Why?
|
Neoplasm Metastasis | 2 | 1986 | 4882 | 0.010 |
Why?
|
Catheterization | 1 | 1983 | 1426 | 0.010 |
Why?
|
Ethiodized Oil | 1 | 1997 | 26 | 0.010 |
Why?
|
Cardiomyopathies | 1 | 1990 | 2068 | 0.010 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 1999 | 869 | 0.010 |
Why?
|
Diarrhea | 1 | 2004 | 1315 | 0.010 |
Why?
|
Verbal Learning | 1 | 2000 | 459 | 0.010 |
Why?
|
Gelatin Sponge, Absorbable | 1 | 1997 | 56 | 0.010 |
Why?
|
Kidney | 1 | 1993 | 7073 | 0.010 |
Why?
|
Risk Factors | 3 | 2014 | 74850 | 0.010 |
Why?
|
Neoplasms, Second Primary | 1 | 2005 | 1056 | 0.010 |
Why?
|
Fatigue | 2 | 1997 | 1553 | 0.010 |
Why?
|
Basal Ganglia | 1 | 2000 | 549 | 0.010 |
Why?
|
Neurologic Examination | 1 | 2000 | 913 | 0.010 |
Why?
|
Mitomycin | 1 | 1997 | 261 | 0.010 |
Why?
|
DNA Topoisomerases, Type I | 1 | 1996 | 108 | 0.010 |
Why?
|
Leucovorin | 1 | 1998 | 643 | 0.010 |
Why?
|
L-Lactate Dehydrogenase | 1 | 1997 | 411 | 0.010 |
Why?
|
Biometry | 1 | 1999 | 571 | 0.010 |
Why?
|
Thrombosis | 1 | 1990 | 2955 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2014 | 20133 | 0.010 |
Why?
|
Cerebral Infarction | 1 | 2000 | 968 | 0.010 |
Why?
|
Hemostatics | 1 | 1997 | 247 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2010 | 10426 | 0.010 |
Why?
|
Alkaline Phosphatase | 1 | 1997 | 855 | 0.010 |
Why?
|
Prostatectomy | 1 | 2001 | 1786 | 0.010 |
Why?
|
Drug Interactions | 1 | 1998 | 1416 | 0.010 |
Why?
|
Mental Recall | 1 | 2000 | 1217 | 0.010 |
Why?
|
Registries | 1 | 2009 | 8346 | 0.010 |
Why?
|
Antibodies, Viral | 2 | 1985 | 3213 | 0.010 |
Why?
|
Leukopenia | 2 | 1984 | 213 | 0.010 |
Why?
|
Prostate-Specific Antigen | 1 | 2001 | 2463 | 0.010 |
Why?
|
Angiography | 1 | 1997 | 1589 | 0.010 |
Why?
|
Psychomotor Performance | 1 | 2000 | 1882 | 0.010 |
Why?
|
Animals | 2 | 2018 | 168735 | 0.010 |
Why?
|
Mice | 1 | 2018 | 81782 | 0.010 |
Why?
|
Radiation Dosage | 1 | 1999 | 1945 | 0.010 |
Why?
|
Abdominal Pain | 1 | 1997 | 1069 | 0.010 |
Why?
|
Brachiocephalic Veins | 1 | 1990 | 21 | 0.010 |
Why?
|
Nausea | 2 | 1985 | 678 | 0.010 |
Why?
|
Prothrombin Time | 1 | 1990 | 117 | 0.010 |
Why?
|
Fever | 1 | 1997 | 1607 | 0.010 |
Why?
|
Vena Cava, Superior | 1 | 1990 | 197 | 0.000 |
Why?
|
Doxorubicin | 2 | 1987 | 2226 | 0.000 |
Why?
|
Occupational Exposure | 1 | 1999 | 1806 | 0.000 |
Why?
|
Phlebography | 1 | 1990 | 326 | 0.000 |
Why?
|
Thioguanine | 1 | 1987 | 45 | 0.000 |
Why?
|
United States | 2 | 2013 | 72909 | 0.000 |
Why?
|
Proportional Hazards Models | 1 | 2001 | 12529 | 0.000 |
Why?
|
Neuropsychological Tests | 1 | 2000 | 7116 | 0.000 |
Why?
|
Lymph Node Excision | 1 | 1993 | 1258 | 0.000 |
Why?
|
Double-Blind Method | 1 | 2000 | 12417 | 0.000 |
Why?
|
Drug Synergism | 1 | 1990 | 1751 | 0.000 |
Why?
|
Blood Cell Count | 1 | 1987 | 404 | 0.000 |
Why?
|
Trinidad and Tobago | 1 | 1985 | 13 | 0.000 |
Why?
|
Deltaretrovirus | 1 | 1985 | 162 | 0.000 |
Why?
|
Cytarabine | 1 | 1987 | 696 | 0.000 |
Why?
|
Brain Mapping | 1 | 2000 | 6598 | 0.000 |
Why?
|
Hypotension | 1 | 1990 | 885 | 0.000 |
Why?
|
Liver | 1 | 1980 | 7559 | 0.000 |
Why?
|
Carcinoma, Renal Cell | 2 | 1990 | 3183 | 0.000 |
Why?
|
Coitus | 1 | 1985 | 133 | 0.000 |
Why?
|
Blood Coagulation | 1 | 1990 | 1171 | 0.000 |
Why?
|
Boston | 1 | 1996 | 9334 | 0.000 |
Why?
|
Models, Biological | 1 | 1999 | 9443 | 0.000 |
Why?
|
Haiti | 1 | 1985 | 553 | 0.000 |
Why?
|
Hypercalcemia | 1 | 1985 | 425 | 0.000 |
Why?
|
Analysis of Variance | 1 | 1990 | 6202 | 0.000 |
Why?
|
Magnetic Resonance Imaging | 1 | 2008 | 36547 | 0.000 |
Why?
|
Edema | 1 | 1985 | 759 | 0.000 |
Why?
|
Adolescent | 2 | 1987 | 88811 | 0.000 |
Why?
|
Radionuclide Imaging | 1 | 1985 | 1985 | 0.000 |
Why?
|
Cyclophosphamide | 1 | 1984 | 2232 | 0.000 |
Why?
|
Vomiting | 1 | 1981 | 646 | 0.000 |
Why?
|
Intestinal Neoplasms | 1 | 1980 | 314 | 0.000 |
Why?
|
Pilot Projects | 1 | 1991 | 8724 | 0.000 |
Why?
|
Bone Marrow | 1 | 1987 | 2916 | 0.000 |
Why?
|
Acute Disease | 1 | 1987 | 7236 | 0.000 |
Why?
|
Thrombocytopenia | 1 | 1981 | 1172 | 0.000 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 1990 | 10380 | 0.000 |
Why?
|
Bone Neoplasms | 1 | 1985 | 2559 | 0.000 |
Why?
|
Melanoma | 1 | 1990 | 5695 | 0.000 |
Why?
|
Age Factors | 1 | 1987 | 18382 | 0.000 |
Why?
|
Research Design | 1 | 1985 | 6204 | 0.000 |
Why?
|
Clinical Trials as Topic | 1 | 1985 | 8037 | 0.000 |
Why?
|
Heart Failure | 1 | 1988 | 11837 | 0.000 |
Why?
|